

# ICOTYDE- icotrokinra tablet, film coated Janssen Biotech, Inc.

## HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ICOTYDE safely and effectively. See full prescribing information for ICOTYDE.

ICOTYDE™ (icotrokinra) tablets, for oral use  
Initial U.S. Approval: 2026

## INDICATIONS AND USAGE

ICOTYDE is an interleukin-23 (IL-23) receptor antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy. ( 1)

## DOSAGE AND ADMINISTRATION

- See the full prescribing information for recommended evaluation and immunizations prior to treatment. ( 2.1)
- Recommended dosage is 200 mg orally once daily. ( 2.2)
- Administer ICOTYDE on an empty stomach with water upon waking. ( 2.2)
- Wait at least 30 minutes after taking ICOTYDE before eating food. ( 2.2)
- For patients who have difficulty swallowing tablets, ICOTYDE can be dispersed in water. ( 2.3)

## DOSAGE FORMS AND STRENGTHS

Tablets: 200 mg ( 3)

## CONTRAINDICATIONS

None. ( 4)

## WARNINGS AND PRECAUTIONS

Infections: Avoid treatment with ICOTYDE in patients with any clinically important active infection until the infection resolves or is adequately treated. If such an infection develops, discontinue ICOTYDE until the infection resolves. ( 5.1)

Tuberculosis (TB): Consider evaluating for TB prior to initiating treatment with ICOTYDE based on clinical judgment. Monitor patients for signs and symptoms of active TB during and after treatment with ICOTYDE. ( 5.2)

Immunizations: Avoid use of live vaccines during treatment with ICOTYDE. ( 5.3)

## ADVERSE REACTIONS

Most common adverse reactions ( $\geq 1\%$ ) are headache, nausea, cough, fungal infection, and fatigue. ( 6.1)

**To report SUSPECTED ADVERSE REACTIONS, contact Janssen Biotech, Inc. at 1-800-526-7736 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

## USE IN SPECIFIC POPULATIONS

Moderate or Severe Renal Impairment: Monitor for potential adverse reactions when ICOTYDE is used in patients with eGFR  $< 60$  mL/min. ( 8.6)

**See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.**

**Revised: 3/2026**

---

## FULL PRESCRIBING INFORMATION: CONTENTS\*

### 1 INDICATIONS AND USAGE

### 2 DOSAGE AND ADMINISTRATION

2.1 Recommended Evaluation and Immunizations Prior to Treatment Initiation

2.2 Recommended Dosage and Administration Instructions

2.3 Alternative Preparation and Administration Instructions for Patients Who Have

Difficulty Swallowing Tablets

### **3 DOSAGE FORMS AND STRENGTHS**

### **4 CONTRAINDICATIONS**

### **5 WARNINGS AND PRECAUTIONS**

5.1 Infections

5.2 Tuberculosis

5.3 Immunizations

### **6 ADVERSE REACTIONS**

6.1 Clinical Trials Experience

### **8 USE IN SPECIFIC POPULATIONS**

8.1 Pregnancy

8.2 Lactation

8.4 Pediatric Use

8.5 Geriatric Use

8.6 Renal Impairment

### **11 DESCRIPTION**

### **12 CLINICAL PHARMACOLOGY**

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

12.6 Immunogenicity

### **13 NONCLINICAL TOXICOLOGY**

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

### **14 CLINICAL STUDIES**

### **16 HOW SUPPLIED/STORAGE AND HANDLING**

### **17 PATIENT COUNSELING INFORMATION**

\* Sections or subsections omitted from the full prescribing information are not listed.

---

## **FULL PRESCRIBING INFORMATION**

### **1 INDICATIONS AND USAGE**

ICOTYDE is indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy.

### **2 DOSAGE AND ADMINISTRATION**

#### **2.1 Recommended Evaluation and Immunizations Prior to Treatment Initiation**

- Consider evaluating patients for tuberculosis (TB) infection prior to initiating treatment with ICOTYDE based on clinical judgment [see *Warnings and Precautions (5.2)*].
- Complete all age-appropriate vaccinations according to current immunization guidelines [see *Warnings and Precautions (5.3)*].

## **2.2 Recommended Dosage and Administration Instructions**

The recommended dosage of ICOTYDE is 200 mg administered orally once daily.

Administer ICOTYDE upon waking on an empty stomach with water. Wait at least 30 minutes after taking ICOTYDE before eating food. Swallow ICOTYDE whole. Do not crush, split, or chew tablets [see *Clinical Pharmacology (12.3)*].

If a patient misses a dose, instruct patients to take the missed dose as soon as possible with a return to normal dosing schedule the following day.

## **2.3 Alternative Preparation and Administration Instructions for Patients Who Have Difficulty Swallowing Tablets**

ICOTYDE 200 mg tablet can also be dispersed in water using the following instructions:

- Place one ICOTYDE tablet in a cup containing at least 120 mL (4 ounces) of water. It may take a few minutes for the tablet to disperse. The tablet may not completely disperse. The mixture may look yellow, milky, or cloudy, and small pieces may be seen in the water which are safe to swallow.
- Gently swirl the cup before drinking and swallowing the full mixture.
- Add at least 120 mL (4 ounces) of additional water to the cup and completely swallow the contents to make sure the whole dose is taken.
- Complete administration of ICOTYDE within 15 minutes of dispersion in water.

## **3 DOSAGE FORMS AND STRENGTHS**

Tablets: 200 mg of icotrokinra, yellowish orange to yellowish brown, oval, film-coated tablets debossed with '200' on one side and 'JNJ' on the other side.

## **4 CONTRAINDICATIONS**

None.

## **5 WARNINGS AND PRECAUTIONS**

### **5.1 Infections**

Medicines that interact with the immune system may increase the risk of infection.

In the 16-week placebo-controlled trials in subjects with moderate-to-severe plaque psoriasis, the rate of serious infections for ICOTYDE-treated subjects was 0.2% compared to 0.4% of subjects who received placebo.

Avoid treatment with ICOTYDE in patients with any clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing ICOTYDE. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection and/or is not responding to standard therapy, monitor the patient closely and discontinue ICOTYDE until the infection resolves.

## 5.2 Tuberculosis

Consider evaluating patients for tuberculosis (TB) infection prior to initiating treatment with ICOTYDE based on clinical judgment. Consider anti-TB therapy prior to initiating ICOTYDE in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after ICOTYDE treatment. Avoid administering ICOTYDE to patients with active TB.

## 5.3 Immunizations

Avoid use of live vaccines in patients during treatment with ICOTYDE. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating therapy with ICOTYDE, complete immunizations according to current immunization guidelines. No data are available on the response to live or inactive vaccines.

## 6 ADVERSE REACTIONS

### 6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of ICOTYDE was evaluated in two placebo-controlled trials (Trial PSO-3 and Trial PSO-4) and two placebo- and active-controlled trials (Trial PSO-1 and Trial PSO-2) [see *Clinical Studies (14)*]. A total of 2367 adults and pediatric subjects 12 years of age and older who weigh at least 40 kg with moderate-to-severe plaque psoriasis received ICOTYDE 200 mg orally once daily. Of these, 648 subjects were treated with ICOTYDE for at least one year.

Data from these four trials were pooled to evaluate the safety of ICOTYDE compared to placebo for 16 weeks.

#### Adverse Reactions

*Weeks 0 to 16*

**Table 1: Adverse Reactions that Occurred in  $\geq 1\%$  of Subjects in the ICOTYDE Group and More Frequently than in the Placebo Group in Trials PSO-1, PSO-2, PSO-3, and PSO-4 through Week 16 \***

<b>Adverse Reactions</b>	<b>ICOTYDE N=1296 n (%)</b>	<b>Placebo N=568 n (%)</b>
Headache	51 (4.1)	19 (3.3)
Nausea	15 (1.2)	3 (0.5)
Cough	15 (1.2)	1 (0.2)
Fungal Infection †	14 (1.1)	0 (0)
Fatigue	15 (1.0)	3 (0.5)

- \* percentages based on Cochran-Mantel-Haenszel (CMH) adjusted proportions.
- † Fungal infection includes tinea pedis (n=4), tinea versicolor (n=2), oral candidiasis (n=2), onychomycosis (n=1), skin candida (n=1), urinary tract candidiasis (n=1), vulvovaginal candidiasis (n=1), fungal skin infection (n=1), genital infection fungal (n=1), ear infection fungal (n=1), laryngitis fungal (n=1). Two subjects experienced more than 1 event.

Adverse reactions that occurred in < 1% of subjects in the ICOTYDE group and at a higher rate than in the placebo group through Week 16 in Trials PSO-1, PSO-2, PSO-3, and PSO-4 were: gastritis, abdominal discomfort, and one fatal case involving upper gastrointestinal bleeding in a subject with underlying risk factors. A relationship of this event to ICOTYDE is not established.

### Adverse Reactions in Pediatric Subjects 12 Years of Age and Older

The safety of ICOTYDE was evaluated in pediatric subjects 12 years of age and older who weigh at least 40 kg with moderate-to-severe plaque psoriasis in two placebo-controlled trials (Trial PSO-3 and Trial PSO-4). A total of 72 pediatric subjects were treated with ICOTYDE 200 mg orally once daily. Of these, 45 subjects were treated with ICOTYDE for at least one year. The adverse reactions observed in pediatric subjects were consistent with the most common adverse reactions ( $\geq 1\%$ ) observed in the overall population.

## **8 USE IN SPECIFIC POPULATIONS**

### **8.1 Pregnancy**

#### Risk Summary

The available data on the use of ICOTYDE during pregnancy are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In an animal reproduction study in rabbits, oral administration of icotrokinra to pregnant rabbits during the period of organogenesis at a dose 157 times the maximum recommended human dose (MRHD) based on AUC comparison resulted in maternal body weight loss, low food consumption, late pregnancy loss, and an increased fetal incidence of fused ribs (*see Data*).

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defects, loss, and other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

There is a pregnancy safety study for ICOTYDE. If a patient becomes pregnant while receiving ICOTYDE, healthcare providers can report ICOTYDE exposure by calling 1-800-526-7736 or visiting [www.ICOTYDE.com](http://www.ICOTYDE.com).

#### Data

##### *Animal Data*

In an embryo-fetal development study, icotrokinra was administered to pregnant rats during the period of organogenesis at oral doses of 70, 200, and 1000 mg/kg/day. No maternal or embryo-fetal toxicity was observed at doses up to 1000 mg/kg/day (297

times the MRHD based on AUC comparison). In another embryo-fetal development study, icotrokinra was administered to pregnant rabbits during the period of organogenesis at oral doses of 50, 200, and 500 mg/kg/day. Maternal body weight loss, low food consumption, late pregnancy loss, and an increased fetal incidence of fused ribs were observed at 500 mg/kg/day (157 times the MRHD based on AUC comparison). No maternal or embryo-fetal toxicity was noted at doses up to 200 mg/kg/day in rabbits (27 times the MRHD based on AUC comparison).

In a pre- and post-natal development study in rats, icotrokinra was administered to pregnant rats during pregnancy and lactation periods at oral doses of 20, 70, and 200 mg/kg/day. No maternal or developmental toxicity was noted in doses up to 200 mg/kg/day (127 times the MRHD based on AUC comparison).

## **8.2 Lactation**

### Risk Summary

There are no data on the presence of icotrokinra in human milk, the effects on the breastfed infant, or the effects on milk production. When administered to lactating rats, icotrokinra was detected in the plasma of nursing pups (*see Data*). When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ICOTYDE and any potential adverse effects on the breastfed infant from ICOTYDE or from the underlying maternal condition.

### Data

In a pre- and post-natal development study in rats, icotrokinra was administered orally to pregnant rats during pregnancy and lactation periods at doses up to 200 mg/kg/day (127 times the MRHD based on AUC comparison). Although not directly measured in rat milk, icotrokinra was detected in the plasma of nursing rat pups. No adverse developmental effects were observed in the nursing pups.

## **8.4 Pediatric Use**

The safety and effectiveness of ICOTYDE have been established in pediatric patients 12 years of age and older who weigh at least 40 kg with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Use of ICOTYDE for this indication is supported by evidence from two multi-center, randomized 52-week trials (Trial PSO-3 and Trial PSO-4) conducted in adults and pediatric subjects, including 72 pediatric subjects 12 years of age and older treated with ICOTYDE [*see Adverse Reactions (6.1) and Clinical Studies (14)*].

The safety and effectiveness of ICOTYDE in pediatric patients younger than 12 years of age or who weigh less than 40 kg have not been established.

## **8.5 Geriatric Use**

Of the 2367 subjects exposed to ICOTYDE in clinical trials for moderate-to-severe plaque psoriasis, 240 (10.1%) were 65 years of age and older, and 36 (1.5%) were 75 years of age and older. No overall differences in safety and effectiveness of ICOTYDE have been observed between subjects 65 years of age and older and younger adult subjects [*see Clinical Studies (14)*].

## 8.6 Renal Impairment


Monitor for potential adverse reactions when ICOTYDE is used in patients with an estimated glomerular filtration rate (eGFR) <60 mL/min [see *Clinical Pharmacology* (12.3)] .

## 11 DESCRIPTION

Icotrokinra is an IL-23 receptor antagonist, in the form of a hydrochloride salt. Icotrokinra is a 13-amino acid peptide. The molecular formula for icotrokinra is C<sub>90</sub>H<sub>120</sub>N<sub>20</sub>O<sub>22</sub>S<sub>2</sub> and its molecular weight is 1898.17.

The chemical name for icotrokinra is (4S)-4-[[[4-[(2S)-2-[(2S)-2-[[[(4R,7S,10S,13S,16S,19R)-19-acetamido-7-(4-acetamidobutyl)-16-(2-amino-2-oxoethyl)-13-[(1R)-1-hydroxyethyl]-3,3,20,20-tetramethyl-10-[(7-methyl-1H-indol-3-yl)methyl]6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan-4-yl]carbonyl)amino]-3-[4-(2-aminoethoxy)phenyl]propanamido]-3-(2-naphthyl)propanamido]tetrahydro-2H-pyran-4-yl]carbonyl)amino]-5-[[[(2S)-4-amino-1-[[[(2S)-1-[(2-amino-2-oxoethyl)(methyl)amino]-1-oxo-3-(pyridin-3-yl)propan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-oxopentanoic acid.

The structural formula for icotrokinra hydrochloride is:



Icotrokinra hydrochloride is a white to almost white powder. It is freely soluble below pH 2, very slightly soluble at pH 5, practically insoluble at pH 9, and freely soluble above pH 11. The isoelectric point (pI) of the compound is 7.15.

ICOTYDE™ (icotrokinra) tablets are supplied as 200 mg film-coated tablets for oral administration. Each tablet of ICOTYDE contains 200 mg icotrokinra (equivalent to 201.6–202.8 mg of icotrokinra hydrochloride) and the following inactive ingredients: colloidal silicon dioxide, crospovidone, magnesium stearate, and silicified microcrystalline cellulose. The film coating contains the following inactive ingredients: glyceryl monocaprylocaprate, iron oxide yellow, macrogol polyvinyl alcohol graft polymer,

polyvinyl alcohol partially hydrolyzed, talc, and titanium dioxide.

## 12 CLINICAL PHARMACOLOGY

### 12.1 Mechanism of Action

Icotrokinra is a peptide that selectively binds to the IL-23 receptor (IL-23R) with a dissociation constant of 7 pM and antagonizes the binding of IL-23. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Icotrokinra inhibits the IL-23/IL-23R-dependent release of proinflammatory cytokines.

### 12.2 Pharmacodynamics

Icotrokinra reduced serum levels of proinflammatory cytokines, IL-17A, IL-17F, IL-19, IL-22 and  $\beta$ -defensin-2, relative to pretreatment levels in evaluated subjects with moderate-to-severe plaque psoriasis based on exploratory analysis of the pharmacodynamic markers. A decrease from baseline was observed in the expression of mRNA related to IL-23/Th17 pathway and psoriasis, including molecular targets *IL17A*, *IL17F*, *IL19*, *IL22*, *IL23A*, and *DEFB4A*, in lesional skin biopsies up to 24 weeks post treatment in an exploratory analysis of subjects with moderate-to-severe plaque psoriasis. The relationship between these pharmacodynamic markers and the mechanism(s) by which icotrokinra exerts its clinical effects is not fully understood.

#### Cardiac Electrophysiology

At 5 times the maximum recommended dose of ICOTYDE, clinically significant QTc interval prolongation was not observed.

### 12.3 Pharmacokinetics

Following the administration of icotrokinra 200 mg, the mean (standard deviation) maximum concentration ( $C_{max}$ ) is 3.62 (1.48) ng/mL and total systemic exposure ( $AUC_{inf}$ ) is 44.8 (11.4) ng\*h/mL. Icotrokinra  $C_{max}$  and  $AUC$  increase in a dose-proportional manner between 0.05 to 5 times the recommended dosage in healthy subjects.

Following multiple dose administration accumulation for  $C_{max}$  was up to 1.6-fold and for  $AUC$  was up to 1.5-fold. Icotrokinra steady state is reached in approximately 3 days.

No clinically relevant differences in icotrokinra pharmacokinetics were observed between healthy subjects and patients with moderate-to-severe plaque psoriasis.

#### Absorption

Icotrokinra median (min, max) time to maximum plasma concentration ( $T_{max}$ ) is 2 (0.25, 8) hours.

#### *Effect of Food*

Icotrokinra  $AUC$  decreased by 43% and  $C_{max}$  decreased by 59% following administration with a high-fat meal (1000 calories, 50% fat) [see *Dosage and Administration (2.2)*].

No clinically significant differences in icotrokinra pharmacokinetics were observed following administration of caffeine.

#### Distribution

Icotrokinra is 52% bound to plasma protein. Blood to plasma partition ratio is 0.53. Icotrokinra steady state apparent (oral) volume of distribution is 92800 L.

### Elimination

Icotrokinra median elimination half-life is 12 hours with an apparent (oral) clearance of 6550 L/h.

### *Metabolism*

Icotrokinra is a peptide and it is metabolized by peptide catabolism into smaller peptides.

### *Excretion*

Following oral administration of icotrokinra to healthy subjects, approximately 37% to 81% of the dose was recovered in feces within 24 hours as unchanged icotrokinra, and 0.001% of the dose was recovered in urine as unchanged icotrokinra.

### Specific Populations

No clinically significant differences in the pharmacokinetics of icotrokinra were observed based on age (range: 12 to 87 years), body weight (range: 39 to 211 kg), sex, race (76% White, 20.1% Asian, 1.7% Black), ethnicity, immunogenicity, mild (eGFR  $\geq$ 60 to  $<$ 90 mL/min, [calculated according to Chronic Kidney Disease Epidemiology Collaboration]) renal impairment. The effect of mild (Child-Pugh Class A) to severe (Child-Pugh Class C) hepatic impairment on icotrokinra pharmacokinetics is unknown. Hepatic impairment is unlikely to affect icotrokinra elimination since the drug is not metabolized hepatically. However, patients with severe hepatic impairment were not studied in clinical trials.

### *Pediatric Patients*

No clinically relevant differences in icotrokinra pharmacokinetics were observed in pediatric patients with moderate-to-severe plaque psoriasis 12 years of age and older who weigh at least 40 kg compared to adults.

### *Patients with Renal Impairment*

Icotrokinra AUC increased by 2.47-fold in patients with moderate (eGFR  $\geq$ 30 to  $<$ 60 mL/min, [calculated according to Chronic Kidney Disease Epidemiology Collaboration]) and 2.78-fold in severe (eGFR  $\geq$ 15 to  $<$ 30 mL/min) renal impairment. No clinically significant differences in the pharmacokinetics of icotrokinra were observed in patients with mild renal impairment (eGFR  $\geq$ 60 to  $<$ 90 mL/min) based on population pharmacokinetic analysis.

### Drug Interaction Studies

#### *Clinical Studies*

No formal drug-drug interaction studies have been conducted with icotrokinra. No clinically significant drug interactions have been identified.

#### *In Vitro Studies*

**CYP450 Enzymes:** Icotrokinra does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4. Icotrokinra does not induce CYP1A2, CYP2B6, and CYP3A4.

**Transporter systems:** Icotrokinra is not a substrate of P-gp, BCRP, OATP1B1, OATP1B3,

OAT1, OAT3, OCT2, MATE1, and MATE2-K. Icotrokinra does not inhibit P-gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, MATE2-K, and BSEP.

## 12.6 Immunogenicity

The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of ICOTYDE or of other icotrokinra products.

In four Phase 3 clinical studies through Week 52, 9.6% (199/2083) of subjects treated with ICOTYDE developed anti-drug antibodies. No neutralizing antibodies were detected.

Among ICOTYDE-treated subjects who developed anti-drug antibodies, population pharmacokinetic analysis using pooled data through Week 52 showed that icotrokinra  $C_{max}$  increased by 1.2-fold and AUC increased by 1.3-fold.

There was no identified clinically relevant effect of anti-drug antibodies on pharmacokinetics, pharmacodynamics, safety or effectiveness of ICOTYDE over the treatment duration of 52 weeks.

## 13 NONCLINICAL TOXICOLOGY

### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

In a 6-month transgenic rasH2 mouse study, no drug-related tumors were observed at oral doses of icotrokinra up to 500 mg/kg/day (76 times the MRHD based on AUC comparison). In a 2-year rat carcinogenicity study, no drug-related tumors were observed at oral doses of 20 mg/kg/day (16 times the MRHD based on AUC comparison).

Icotrokinra was not genotoxic in an *in vitro* bacterial reverse mutation assay (the Ames test), an *in vitro* human lymphocyte chromosomal aberration assay, or an *in vivo* rat micronucleus and Comet assays.

In male rats, icotrokinra had no adverse effect on mating, fertility or early embryonic development of their offspring at oral doses up to 20 mg/kg/day (114 times the MRHD based on AUC comparison).

In female rats, icotrokinra had no adverse effect on estrous cyclicity, mating, fertility, or early embryonic parameters at oral doses up to 70 mg/kg/day (335 times the MRHD based on AUC comparison).

## 14 CLINICAL STUDIES

The efficacy of ICOTYDE was evaluated in four multi-center, randomized, double-blind, placebo and/or active comparator-controlled trials (Trial PSO-1 [NCT06143878], Trial PSO-2 [NCT06220604], Trial PSO-3 [NCT06095115], and Trial PSO-4 [NCT06095102]) that included 2500 subjects (2428 adults and 72 pediatric subjects 12 years and older who weigh at least 40 kg) with moderate-to-severe plaque psoriasis who were eligible for systemic therapy or phototherapy.

## Adults with Moderate-to-Severe Plaque Psoriasis (Trials PSO-1 and PSO-2)

### *Trial Design*

Trial PSO-1 and Trial PSO-2 enrolled 1505 adults with moderate-to-severe plaque psoriasis defined as Investigator's Global Assessment (IGA) score  $\geq 3$ , a Psoriasis Area and Severity Index (PASI) score  $\geq 12$ , and body surface area (BSA) involvement  $\geq 10\%$ .

Subjects were randomized to either ICOTYDE 200 mg orally once daily, deucravacitinib 6 mg orally once daily or placebo. At Week 16, subjects originally randomized to placebo received ICOTYDE 200 mg orally once daily thereafter. At Week 24, subjects originally randomized to deucravacitinib received ICOTYDE 200 mg orally once daily thereafter.

### *Baseline Characteristics*

Baseline characteristics were consistent across both trials. In Trial PSO-1 and Trial PSO-2, 68% of subjects were male, 78% of subjects were White, 2% of subjects were Black, and 18% of subjects were Asian; for ethnicity, 16% identified as Hispanic or Latino. The mean age was 46 (range: 18 to 86) years, and the mean baseline weight was 88 kg. At baseline, subjects had a median affected BSA of 21%, a median PASI score of 18, and 14% had a history of psoriatic arthritis. The proportion of subjects with a baseline IGA score of 4 (severe) was 20%. At baseline, 72% had received prior systemic therapy, 33% of subjects had received prior phototherapy, and 26% had received prior biologic therapy.

### *Clinical Response*

Trial PSO-1 and Trial PSO-2 assessed responses at Week 16 for ICOTYDE compared to placebo for two co-primary endpoints:

- the proportion of subjects who achieved IGA 0/1 response (defined as IGA score of 0 [cleared] or 1 [minimal] with a  $\geq 2$ -grade improvement from baseline)
- the proportion of subjects who achieved at least a 90% improvement in PASI scores from baseline (PASI 90).

Other evaluated outcomes for ICOTYDE compared to placebo included IGA 0, PASI 75, PASI 100, Psoriasis Symptoms and Signs Diary (PSSD) Symptom Score of 0, and PSSD Itch Score improvement from baseline ( $\geq 4$ -point reduction).

Other comparisons between ICOTYDE and deucravacitinib that were secondary endpoints included:

- the proportion of subjects who achieved IGA 0/1 score with at least 2-grade improvement from baseline, IGA 0 score, PASI 75, PASI 90, and PASI 100 at Week 16 and Week 24
- the proportion of subjects who achieved PSSD Symptom Score of 0 at Week 16.

Tables 2 and 3 present the efficacy results in adults with moderate-to-severe plaque psoriasis for Trial PSO-1 and Trial PSO-2.

**Table 2: Efficacy Results in Adults with Moderate-to-Severe Plaque Psoriasis (Trial PSO-1)**

	ICOTYDE (N=311)	Placebo (N=156)	Deucravacitinib (N=307)	Difference, % (95% CI)	
				Difference from	Difference from

Endpoint	n (%)	n (%)	n (%)	from Placebo	from Deucravacitinib
<b>IGA 0 or 1 ("cleared" or "minimal") and a <math>\geq</math>2-grade improvement from baseline)</b>					
* Week 16	213 (68)	17 (11)	154 (50)	58 (50, 64)	18 (11, 26)
Week 24	230 (74)	-	161 (52)	-	22 (14, 29)
<b>IGA 0 ("cleared")</b>					
Week 16	114 (37)	3 (2)	48 (16)	35 (29, 41)	21 (14, 28)
Week 24	150 (48)	-	63 (21)	-	28 (21, 35)
<b>PASI 75</b>					
Week 16	231 (74)	18 (12)	176 (57)	63 (55, 69)	17 (10, 24)
Week 24	254 (82)	-	196 (64)	-	18 (11, 25)
<b>PASI 90</b>					
* Week 16	171 (55)	6 (4)	91 (30)	51 (44, 57)	25 (18, 33)
Week 24	205 (66)	-	127 (41)	-	25 (17, 32)
<b>PASI 100</b>					
Week 16	97 (31)	2 (1)	34 (11)	30 (24, 36)	20 (14, 26)
Week 24	129 (41)	-	49 (16)	-	26 (19, 32)
<b>PSSD Symptom Score 0 †</b>					
N	286	142	272	-	-
Week 16	68 (24)	4 (3)	25 (9)	21 (15, 27)	14 (8, 21)
<b>PSSD Itch Score Improvement (<math>\geq</math>4-point reduction from baseline) ‡</b>					
N	251	115	-	-	-
Week 4	56 (22)	8 (7)	-	15 (8, 22)	-
Week 16	155 (62)	19 (17)	-	45 (35, 54)	-

CI = Confidence interval; PASI = Psoriasis Area and Severity Index; IGA = Investigator's Global Assessment; PSSD = Psoriasis Symptoms and Signs Diary

\* Co-primary endpoints comparing ICOTYDE to placebo.

† Includes subjects with baseline PSSD Symptom Score  $>$ 0.

‡ Includes subjects with baseline PSSD Itch Score  $\geq$ 4.

**Table 3: Efficacy Results in Adults with Moderate-to-Severe Plaque Psoriasis (Trial PSO-2)**

Endpoint	ICOTYDE (N=320) n (%)	Placebo (N=81) n (%)	Deucravacitinib (N=322) n (%)	Difference, % (95% CI)	
				Difference from Placebo	Difference from Deucravacitinib
<b>IGA 0 or 1 ("cleared" or "minimal") and a <math>\geq</math>2-grade improvement from baseline</b>					
* Week 16	227 (71)	7 (9)	177 (55)	63 (53, 70)	16 (9, 23)
Week 24	220 (69)	-	179 (56)	-	13 (6, 21)
<b>IGA 0 ("cleared")</b>					
Week 16	118 (37)	1 (1)	57 (18)	36 (29, 42)	19 (13, 26)
Week 24	128 (40)	-	68 (21)	-	19 (12, 26)

<b>PASI 75</b>					
Week 16	249 (78)	8 (10)	198 (61)	68 (59, 75)	17 (10, 23)
Week 24	265 (83)	-	216 (67)	-	16 (9, 22)
<b>PASI 90</b>					
Week 16*	184 (58)	1 (1)	111 (34)	57 (49, 62)	23 (16, 30)
Week 24	208 (65)	-	141 (44)	-	21 (14, 29)
<b>PASI 100</b>					
Week 16	102 (32)	1 (1)	46 (14)	31 (24, 36)	18 (11, 24)
Week 24	107 (33)	-	52 (16)	-	17 (11, 24)
<b>PSSD Symptom Score 0 †</b>					
N	296	70	282	-	-
Week 16	64 (22)	0	36 (13)	22 (15, 27)	9 (3, 15)
<b>PSSD Itch Score Improvement (≥4-point reduction from baseline) ‡</b>					
N	256	60	-	-	-
Week 4	54 (21)	3 (5)	-	16 (6, 22)	-
Week 16	154 (60)	9 (15)	-	46 (34, 56)	-

CI = Confidence interval; PASI = Psoriasis Area and Severity Index; IGA = Investigator's Global Assessment; PSSD = Psoriasis Symptoms and Signs Diary  
 Trial PSO-2 enrolled 731 subjects, of which 723 subjects were evaluable for efficacy.

\* Co-primary endpoints comparing ICOTYDE to placebo.

† Includes subjects with baseline PSSD Symptom Score >0.

‡ Includes subjects with baseline PSSD Itch Score ≥4.

### Adults and Pediatric Subjects 12 Years of Age and Older with Moderate-to-Severe Plaque Psoriasis (Trial PSO-3)

#### *Trial Design*

Trial PSO-3 enrolled 684 subjects (618 adults and 66 pediatric subjects 12 years of age and older who weigh at least 40 kg) with moderate-to-severe plaque psoriasis defined as Investigator's Global Assessment (IGA) score ≥3, a Psoriasis Area and Severity Index (PASI) score ≥12, and BSA ≥10%.

Subjects were randomized to receive either ICOTYDE (200 mg orally once daily) or placebo for 16 weeks.

#### *Baseline Characteristics*

In Trial PSO-3, 65% of subjects were male, 72% of the subjects were White, 1% of the subjects were Black, and 24% of subjects were Asian; for ethnicity, 13% identified as Hispanic or Latino. The mean age was 43 (range: 12 to 85) years, the mean baseline weight was 86 kg, and 10% were 12 years to less than 18 years of age. At baseline, subjects had a median affected BSA of 20%, a median PASI score of 17, and 13% had a history of psoriatic arthritis. The proportion of subjects with a baseline IGA score of 4 (severe) was 25%. At baseline, 72% had prior systemic treatment, 30% of subjects had received prior phototherapy, and 34% had received prior biologic therapy.

#### *Clinical Response*

Trial PSO-3 assessed responses at Week 16 for ICOTYDE compared to placebo for two

co-primary endpoints:

- the proportion of subjects who achieved IGA 0/1 response (defined as IGA score of 0 [cleared] or 1 [minimal] with a  $\geq 2$ -grade improvement from baseline)
- the proportion of subjects who achieved PASI 90.

Other evaluated outcomes for ICOTYDE compared to placebo included IGA 0, PASI 75, PASI 100, PSSD Symptom Score of 0, and PSSD Itch Score improvement from baseline ( $\geq 4$ -point reduction).

Table 4 presents the efficacy results in adults and pediatric subjects 12 years of age and older for Trial PSO-3.

**Table 4: Efficacy Results in Adults and Pediatric Subjects 12 Years of Age and Older with Moderate-to-Severe Plaque Psoriasis (Trial PSO-3)**

Endpoint	ICOTYDE (N=456) n (%)	Placebo (N=228) n (%)	Difference, % from Placebo (95% CI)
<b>IGA 0 or 1 ("cleared" or "minimal") and a <math>\geq 2</math>-grade improvement from baseline</b>			
Week 16 *	295 (65)	19 (8)	56 (50, 62)
<b>IGA 0 ("cleared")</b>			
Week 16	152 (33)	3 (1)	32 (27, 37)
<b>PASI 75</b>			
Week 16	315 (69)	25 (11)	58 (52, 64)
<b>PASI 90</b>			
Week 16 *	226 (50)	10 (4)	45 (40, 50)
<b>PASI 100</b>			
Week 16	123 (27)	1 (<1)	26 (22, 31)
<b>PSSD Symptom Score 0 †</b>			
N	408	208	-
Week 16	82 (20)	2 (<1)	19 (15, 24)
<b>PSSD Itch Score Improvement (<math>\geq 4</math>-point reduction from baseline) ‡</b>			
N	350	176	-
Week 4	67 (19)	9 (5)	14 (9, 19)
Week 16	203 (58)	23 (13)	45 (37, 52)

CI = Confidence interval; PASI = Psoriasis Area and Severity Index; IGA = Investigator's Global Assessment; PSSD = Psoriasis Symptoms and Signs Diary

\* Co-primary endpoints comparing ICOTYDE to placebo.

† Includes subjects with baseline PSSD Symptom Score  $> 0$ .

‡ Includes subjects with baseline PSSD Itch Score  $\geq 4$ .

### *Maintenance and Durability of Clinical Response*

In Trial PSO-3, adults who were randomized to ICOTYDE 200 mg orally once daily and were PASI 75 responders or IGA 0 or 1 responders at Week 24 were re-randomized to continue ICOTYDE 200 mg orally once daily or withdrawn from therapy (i.e., received placebo).

For adults who were re-randomized and had a PASI 90 response at Week 24, 84% (108/128) of subjects who continued on ICOTYDE maintained PASI 90 response at Week 52 compared to 21% (27/129) of subjects randomized to placebo. For PASI 90 responders at Week 24 who were re-randomized to placebo, the median time to loss of PASI 90 response was approximately 10 weeks.

For adults who were re-randomized and had an IGA 0/1 response at Week 24, 82% (123/150) of subjects who continued on ICOTYDE maintained IGA 0/1 response at Week 52 compared to 23% (35/150) of subjects randomized to placebo. For IGA 0/1 responders at Week 24 who were re-randomized to placebo, the median time to loss of IGA 0/1 response was approximately 10 weeks.

*Pediatric Subjects 12 Years of Age and Older with Moderate-to-Severe Plaque Psoriasis*

Trial PSO-3 included 66 pediatric subjects 12 years of age and older who weigh at least 40 kg.

Table 5 presents the efficacy results in pediatric subjects 12 years of age and older at Week 16 enrolled in Trial PSO-3.

**Table 5: Efficacy Results in Pediatric Subjects 12 Years of Age and Older with Moderate-to-Severe Plaque Psoriasis at Week 16 (Trial PSO-3)**

<b>Endpoint</b>	<b>ICOTYDE n (%)</b>	<b>Placebo n (%)</b>	<b>Difference, % from Placebo (95% CI)</b>
<i>Number of randomized pediatric subjects</i>	44	22	-
<b>IGA 0 or 1 ("cleared" or "minimal") and a <math>\geq 2</math>-grade improvement from baseline</b>	37 (84)	6 (27)	56 (33, 74)
<b>PASI 90</b>	31 (70)	3 (14)	56 (33, 73)

CI = Confidence interval; PASI = Psoriasis Area and Severity Index; IGA = Investigator's Global Assessment

Adults and Pediatric Subjects 12 Years of Age and Older with Moderate-to-Severe Plaque Psoriasis of the Scalp or Genital Area (Trial PSO-4)

*Trial Design*

Trial PSO-4 enrolled 311 subjects (305 adults and 6 pediatric subjects 12 years of age and older who weigh at least 40 kg) with moderate-to-severe plaque psoriasis who had a minimum BSA involvement of  $\geq 1\%$ , an IGA score of  $\geq 2$  and had failed to respond to at least one topical therapy for the treatment of plaque psoriasis. Additionally, subjects in Trial PSO-4 had at least one of the following baseline conditions: ss-IGA score  $\geq 3$  (at least moderate plaque psoriasis of the scalp), static Physician's Global Assessment of Genitalia (sPGA-G) score  $\geq 3$  (at least moderate plaque psoriasis of the genital area), and/or Physician's Global Assessment of Hands and/or Feet (hf-PGA) score  $\geq 3$  (at least moderate plaque psoriasis of the hands and/or feet).

Subjects were randomized to receive either ICOTYDE 200 mg orally once daily or placebo for 16 weeks. At Week 16, subjects originally randomized to placebo switched to receive ICOTYDE 200 mg orally once daily, and subjects randomized to ICOTYDE at baseline remained on treatment through the end of study.

### *Baseline Characteristics*

In Trial PSO-4, 64% of subjects were male, 78% of subjects were White, 1% of subjects were Black, and 20% of subjects were Asian; for ethnicity, 7% identified as Hispanic or Latino. The mean age was 45 (range: 12 to 87) years, the mean baseline weight was 86 kg, and 2% were 12 years to less than 18 years of age. The proportion of subjects with affected BSA less than 10% was 36% with a median affected BSA of 12%. Subjects had a median PASI score of 14, and 16% had a history of psoriatic arthritis. The proportion of subjects with a baseline IGA score of 3 (moderate), and 4 (severe) were 73% and 22%, respectively. The proportion of subjects with ss-IGA score of 3 or greater was 81%. The proportion of subjects with sPGA-G score of 3 or greater was 45%. The proportion of subjects with hf-PGA score of 3 or greater was 23%. Scalp, genital and hand/foot subpopulations were not mutually exclusive. At baseline, 73% had received prior systemic therapy, 39% of subjects had received prior phototherapy, and 33% had received prior biologic therapy.

### *Clinical Response*

In Trial PSO-4, the primary endpoint was the proportion of subjects who achieved an IGA 0/1 response (defined as IGA score of 0 [cleared] or 1 [minimal] and a  $\geq 2$ -grade improvement from baseline at Week 16).

Other secondary endpoints at Week 16 included proportion of subjects who achieved ss-IGA score of 0 (absence of disease) or 1 (very mild disease), Psoriasis Scalp Severity Index (PSSI) 90, improvement in scalp itch as measured by Scalp Itch Numerical Rating Scale (NRS) Score, sPGA-G score of 0 (clear) or 1 (minimal), improvement of genital itch severity as measured by a reduction of at least 4 points in the 11-point Genital Psoriasis Symptoms Scale (GPSS) Genital Itch NRS Score, and the patient-perceived impact of psoriasis of the genital area on limiting frequency of sexual activity (intercourse or other activities) as measured by the Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) Item 2.

Table 6 presents the efficacy results in adults and pediatric subjects 12 years of age and older at Week 16 for Trial PSO-4.

**Table 6: Efficacy Results in Adults and Pediatric Subjects 12 Years of Age and Older with Moderate-to-Severe Plaque Psoriasis of the Scalp or Genital Area at Week 16 (Trial PSO-4)**

<b>Endpoint</b>	<b>ICOTYDE n (%)</b>	<b>Placebo n (%)</b>	<b>Difference, % from Placebo (95% CI)</b>
<i>Number of randomized subjects</i>	208	103	-
<b>IGA 0 or 1 ("cleared" or "minimal") and a <math>\geq 2</math>-grade improvement from baseline *</b>	118 (57)	6 (6)	51 (42, 59)
<i>Number of subjects with baseline ss-IGA score of <math>\geq 3</math></i>	167	85	-

<b>ss-IGA 0 or 1 ("absence of disease" or "very mild disease") (scalp)</b>	110 (66)	9 (11)	56 (45, 64)
<b>PSSI 90</b>	96 (57)	5 (6)	52 (42, 60)
<i>Number of subjects with baseline Scalp Itch NRS score <math>\geq 4</math> and baseline ss-IGA score <math>\geq 3</math></i>	131	58	-
<b>Scalp Itch NRS score (<math>\geq 4</math>-point improvement)</b>	77 (59)	5 (9)	50 (38, 61)
<i>Number of subjects with baseline sPGA-G score of <math>\geq 3</math></i>	98	42	-
<b>sPGA-G 0 or 1 ("clear" or "minimal") (genitalia)</b>	75 (77)	9 (21)	55 (39, 68)
<i>Number of subjects with baseline GPSS Genital Itch NRS score <math>\geq 4</math> and baseline sPGA-G score <math>\geq 3</math></i>	69	31	-
<b>GPSS Genital Itch NRS score (<math>\geq 4</math>-point improvement)</b>	44 (64)	4 (13)	50 (31, 64)
<i>Number of subjects with baseline GenPs-SFQ Item 2 score <math>\geq 2</math> and baseline sPGA-G score <math>\geq 3</math></i>	55	25	-
<b>GenPs-SFQ Item 2 score 0 or 1 ("never" or "rarely") (genitalia)</b>	44 (80)	9 (36)	43 (20, 62)

CI = Confidence interval; IGA = Investigator's Global Assessment; ss-IGA = Scalp-specific Investigator Global Assessment; PSSI = Psoriasis Scalp Severity Index; NRS = Numerical Rating Scale; sPGA-G = Static Physician's Global Assessment of Genitalia; GPSS = Genital Psoriasis Symptoms Scale; GenPs-SFQ = Genital Psoriasis Sexual Frequency Questionnaire

\* Primary endpoint comparing ICOTYDE to placebo.

### Subgroup Analyses of Trials PSO-1, PSO-2, PSO-3 and PSO-4

An examination of age, gender, race, body weight, baseline disease severity, and previous treatment with systemic or biologic agents did not identify differences in response to ICOTYDE among these subgroups.

## **16 HOW SUPPLIED/STORAGE AND HANDLING**

### How Supplied

ICOTYDE™ (icotrokinra) tablets: 200 mg, yellowish orange to yellowish brown, oval, film-coated tablets debossed with '200' on one side and 'JNJ' on the other side.

ICOTYDE is supplied in bottles of 30 tablets (NDC Number: 57894-201-30), with a silica gel desiccant and a child-resistant closure.

### Storage and Handling

Store at 20 °C to 25 °C (68 °F to 77 °F); excursions permitted between 15 °C to 30 °C

(59 °F to 86 °F) [see USP Controlled Room Temperature]. Store in original package to protect from moisture. Do not discard desiccant.

## 17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

### Infections

Instruct patients of the importance of communicating any history of infections to the healthcare provider and contacting their healthcare provider if they develop any symptoms of an infection [see *Warnings and Precautions (5.1)*] .

### Tuberculosis

Advise patients to contact their healthcare provider if they experience symptoms suggestive of TB (e.g., unexplained fever, cough, or difficulty breathing) [see *Warnings and Precautions (5.2)*] .

### Immunizations

Instruct patients to inform their healthcare provider that they are taking ICOTYDE prior to a potential vaccination [see *Warnings and Precautions (5.3)*] .

### Dosage and Administration

Instruct patients to take ICOTYDE once daily upon waking on an empty stomach with water. Instruct patients to wait at least 30 minutes after taking ICOTYDE before eating food [see *Dosage and Administration (2.2)*] .

Instruct patients who have trouble swallowing tablets to disperse the tablet in water [see *Dosage and Administration (2.3)*] .

### Pregnancy

Advise pregnant women that there is a pregnancy safety study that monitors pregnancy outcomes in women exposed to ICOTYDE during pregnancy, and they can be enrolled by calling 1-800-526-7736 or [www.ICOTYDE.com](http://www.ICOTYDE.com) [see *Use in Specific Populations (8.1)*].

Manufactured for:  
Janssen Biotech, Inc.  
Horsham, PA 19044, USA

For patent information: [www.janssenpatents.com](http://www.janssenpatents.com)

© Johnson & Johnson and its affiliates 2026

<p style="text-align: center;"><b>MEDICATION GUIDE</b> <b>ICOTYDE™ (ai-koh-tide)</b> <b>(icotrokinra)</b> <b>tablets, for oral use</b></p>
--

<p><b>What is the most important information I should know about ICOTYDE?</b></p>
---

- |   |
|---|
| <ul style="list-style-type: none"><li>• <b>Infections.</b> Medicines that interact with the immune system, such as ICOTYDE, may lower your ability to fight infections and may increase your risk of infections. Your healthcare provider may check you for infections and tuberculosis (TB) before starting treatment and may treat you for TB before you begin treatment with</li></ul> |
|---|

ICOTYDE if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with ICOTYDE. Tell your healthcare provider right away if you have any infection or have symptoms of an infection, including:

- fever, sweat, or chills
- cough
- shortness of breath
- blood in your mucus (phlegm)
- muscle aches
- warm, red, or painful skin or sores on your body different from your psoriasis
- weight loss
- diarrhea or stomach pain
- burning when you urinate or urinating more often than normal

See "**What are the possible side effects of ICOTYDE?**" for more information about side effects.

### **What is ICOTYDE?**

ICOTYDE is a prescription medicine used to treat moderate-to-severe plaque psoriasis in adults and children 12 years of age and older who weigh at least 88 pounds (40 kg), who may benefit from taking injections or medicines by mouth (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).

It is not known if ICOTYDE is safe and effective in children under 12 years of age or who weigh less than 88 pounds (40 kg).

### **Before taking ICOTYDE, tell your healthcare provider about all of your medical conditions, including if you:**

- have an infection that does not go away or that keeps coming back.
- have tuberculosis (TB) or have been in close contact with someone with TB.
- have recently received or are scheduled to receive an immunization (vaccine). Avoid receiving live vaccines during treatment with ICOTYDE.
- have kidney problems.
- are pregnant or plan to become pregnant. It is not known if ICOTYDE can harm your unborn baby.

**Pregnancy Safety Study.** There is a pregnancy safety study for women who take ICOTYDE during pregnancy. The purpose of this study is to collect information about the health of you and your baby. If you are pregnant or become pregnant during treatment with ICOTYDE, you can report your pregnancy by calling 1-800-526-7736 or visiting [www.ICOTYDE.com](http://www.ICOTYDE.com).

- are breastfeeding or plan to breastfeed. It is not known if ICOTYDE passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with ICOTYDE.

**Tell your healthcare provider about all the medicines you take,** including prescription and over-the-counter medicines, vitamins, and herbal supplements.

### **How should I take ICOTYDE?**

- Take ICOTYDE exactly as your healthcare provider tells you to take it.
- Take ICOTYDE 1 time a day.
- Take ICOTYDE when you wake up on an empty stomach with water.
- Wait at least 30 minutes after taking ICOTYDE before eating food.
- Swallow ICOTYDE tablets whole.
- **Do not** crush, split, or chew ICOTYDE tablets.
- If you cannot swallow ICOTYDE tablets whole:
  - Place 1 ICOTYDE tablet in a cup containing at least 120 mL (4 ounces) of water.

- Wait a few minutes for the tablet to break up (disperse) in the water. The tablet may not completely disperse. The mixture may look yellow, milky, or cloudy. Small pieces may be seen in the water, which are safe to swallow.
- Gently swirl the cup before swallowing the mixture.
- Add at least 120 mL (4 ounces) of additional water to the cup and completely swallow all of the mixture to make sure that you take your full dose of ICOTYDE.
- Take the ICOTYDE and water mixture within 15 minutes of preparation.
- If you miss a dose of ICOTYDE, take the dose as soon as you remember and go back to your regular schedule the next day.

### **What are the possible side effects of ICOTYDE?**

**ICOTYDE may cause serious side effects. See "What is the most important information I should know about ICOTYDE?"**

**The most common side effects of ICOTYDE include:**

- headache
- nausea
- cough
- fungal infection
- tiredness

These are not all the possible side effects of ICOTYDE.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

### **How should I store ICOTYDE?**

- Store ICOTYDE at room temperature between 68°F to 77°F (20°C to 25°C).
- Store ICOTYDE in the original bottle to protect from moisture.
- The ICOTYDE bottle comes with a child-resistant cap and contains a desiccant packet to keep your medicine dry (protect it from moisture). Do not throw away (discard) the desiccant packet.

**Keep ICOTYDE and all medicines out of the reach of children.**

### **General information about the safe and effective use of ICOTYDE.**

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ICOTYDE for a condition for which it was not prescribed. Do not give ICOTYDE to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ICOTYDE that is written for health professionals.

### **What are the ingredients of ICOTYDE?**

**Active ingredient:** icotrokinra

**Inactive ingredients:** colloidal silicon dioxide, crospovidone, magnesium stearate, and silicified microcrystalline cellulose. The film coating contains glyceryl monocaprylocaprate, iron oxide yellow, macrogol polyvinyl alcohol graft polymer, polyvinyl alcohol partially hydrolyzed, talc, and titanium dioxide.

Manufactured for: Janssen Biotech, Inc., Horsham, PA 19044, USA

For patent information: [www.janssenpatents.com](http://www.janssenpatents.com)

© Johnson & Johnson and its affiliates 2026

For more information, go to [www.ICOTYDE.com](http://www.ICOTYDE.com) or call 1-800-526-7736.

This Medication Guide has been approved by the U.S. Food and Drug Administration. Issued: 3/2026

**PRINCIPAL DISPLAY PANEL - 200 mg Tablet Bottle Carton**

Rx only

NDC 57894-201-30

ICOTYDE™

(icotrokinra) tablets

200 mg

oral use

Attention: Dispense the enclosed  
Medication Guide to each patient.

30 film-coated tablets

Johnson  
&Johnson



# ICOTYDE

icotrokinra tablet, film coated

## Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:57894-201
<b>Route of Administration</b>	ORAL		

**Active Ingredient/Active Moiety**

Ingredient Name	Basis of Strength	Strength
ICOTROKINRA (UNII: MUW8FP7HNZ) (ICOTROKINRA - UNII:MUW8FP7HNZ)	ICOTROKINRA	200 mg

**Inactive Ingredients**

Ingredient Name	Strength
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	
CROSPROVIDONE, UNSPECIFIED (UNII: 2S7830E561)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
SILICIFIED MICROCRYSTALLINE CELLULOSE (125 .MICRO.M, HIGH-DENSITY) (UNII: GRV5BG8C5N)	
GLYCERYL MONOCAPRYLOCAPRATE (UNII: G7515SW10N)	
FERRIC OXIDE YELLOW (UNII: EX43802MRT)	
POLYVINYL ALCOHOL GRAFT POLYETHYLENE GLYCOL COPOLYMER (3:1; 45000 MW) (UNII: 23ZQ42JZZH)	
POLYVINYL ALCOHOL, UNSPECIFIED (UNII: 532B59J990)	
TALC (UNII: 7SEV7J4R1U)	
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)	

**Product Characteristics**

Color	yellow (Yellowish orange to yellowish brown)	Score	no score
Shape	OVAL (oblong)	Size	19mm
Flavor		Imprint Code	200;JNJ
Contains			

**Packaging**

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:57894-201-30	1 in 1 CARTON	03/17/2026	
1		30 in 1 BOTTLE; Type 0: Not a Combination Product		
2	NDC:57894-201-07	1 in 1 CARTON	03/17/2026	
2	NDC:57894-201-01	7 in 1 BLISTER PACK; Type 0: Not a Combination Product		

**Marketing Information**

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA220149	03/17/2026	

**Labeler** - Janssen Biotech, Inc. (099091753)**Establishment**

Name	Address	ID/FEI	Business Operations
Janssen Pharmaceutica NV		400345889	api manufacture(57894-201) , analysis(57894-201)

## Establishment

Name	Address	ID/FEI	Business Operations
Janssen Cilag SpA		542797928	analysis(57894-201) , manufacture(57894-201) , pack(57894-201) , label(57894-201)

## Establishment

Name	Address	ID/FEI	Business Operations
Johnson & Johnson Private Limited		677603030	analysis(57894-201)

## Establishment

Name	Address	ID/FEI	Business Operations
JOM PHARMACEUTICAL SERVICES, LLC		002539707	pack(57894-201) , label(57894-201)

## Establishment

Name	Address	ID/FEI	Business Operations
SGS India Private Limited		650786127	analysis(57894-201)

Revised: 3/2026

Janssen Biotech, Inc.